Ascentage Pharma Group International vs Ultragenyx Pharmaceutical
AAPG and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and RARE compare
Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus −41.5% for Ascentage Pharma Group International).
Ultragenyx Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of −81.7% compared with −216% at Ascentage Pharma Group International.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | RARE |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.6B |
| Share price | $13.14 | $16.70 |
| Change, 1 year | −61.7% | −49.5% |
| Change, 5 years | – | −78.2% |
| Beta (5Y) | 1.43 | 2.12 |
| Employees | 767 | 1,371 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.3× |
| FCF yield | – | −29.7% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 17.5% (better) |
| Revenue growth, 5Y average | – | 19.9% |
| Profitability | ||
| Gross margin | 91.5% | – |
| Operating margin | – | −73.6% |
| Net margin | −216% | −81.7% (better) |
| FCF margin | −209% | −68.2% (better) |
| Return on equity | −156% | – |
| Financial health | ||
| Debt / equity | 1.50 | – |
| Current ratio | 1.79 (better) | 1.73 |
| Altman Z-score | – | −5.26 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 108% |
| Held by insiders | 13.0% | 4.0% |
| Insider net buying, 12 months | – | −$3.8M |
| Short interest, % of float | – | 25.0% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.